SYN - Synthetic Biologics, Inc.
0.5900 +0.01 (2.06%)
Before hours: 5:18AM EDT
Chart Events
Performance Outlook
- Short Term2W - 6W
- Mid Term6W - 9M
- Long Term9M+
| Previous Close | 0.7104 |
| Open | 0.6510 |
| Bid | 0.0000 x 1400 |
| Ask | 0.7201 x 1200 |
| Day's Range | 0.5750 - 0.6880 |
| 52 Week Range | 0.2500 - 0.7500 |
| Volume | 2,102,402 |
| Avg. Volume | 619,909 |
| Market Cap | 10.558M |
| Beta (5Y Monthly) | 1.95 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.9250 |
| Earnings Date | May 05, 2020 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 1.38 |
- PR Newswire
Synthetic Biologics Announces Submission of IND Application to U.S. FDA for SYN-020 Intestinal Alkaline Phosphatase
Synthetic Biologics, Inc. (NYSE American: SYN), a diversified clinical-stage company leveraging the microbiome to develop therapeutics designed to prevent and treat gastrointestinal ("GI") diseases in areas of high unmet need, today announced that it submitted an Investigational New Drug ("IND") application with the U.S. Food and Drug Administration ("FDA") for its SYN-020 Intestinal Alkaline Phosphatase ("IAP") program. The IND application supports an initial indication of SYN-020 for the treatment of radiation enteropathy secondary to pelvic cancer therapy. Under the IND application, the Company intends to conduct a Phase 1 single ascending dose study in healthy volunteers, designed to evaluate SYN-020 for safety, tolerability, and pharmacokinetic parameters.
- Thomson Reuters StreetEvents
Edited Transcript of SYN.A earnings conference call or presentation 5-May-20 8:30pm GMT
Q1 2020 Synthetic Biologics Inc Earnings Call
- PR Newswire
Synthetic Biologics Enters into Exclusive Option to License Intellectual Property for Use of SYN-020 to Treat and Prevent Age-Related Metabolic and Inflammatory Diseases
Synthetic Biologics, Inc. (NYSE American: SYN), a diversified clinical-stage company leveraging the microbiome to develop therapeutics designed to prevent and treat gastrointestinal ("GI") diseases in areas of high unmet need, today announced that it entered into an agreement with Massachusetts General Hospital ("MGH") granting the Company an option for an exclusive license to intellectual property and technology related to the use of intestinal alkaline phosphatase ("IAP") to maintain GI and microbiome health, diminish systemic inflammation, and treat age-related diseases. If executed, the Company plans to use this license in the advancement of an expanded clinical development program for SYN-020, the Company's proprietary recombinant version of bovine IAP currently in pre-clinical development.
- GlobeNewswire
Sýn hf.: Q1 2020 affected by the COVID-19 pandemic
Sýn hf.’s Condensed Consolidated Interim Financial Statements for Q1 2020 was approved by the board on May 13th, 2020. • Revenue for the first quarter (Q1) of 2020 amounted to ISK 4,995 million, on par with the same period in 2019. • The quarter’s EBITDA amounted to ISK 1,355 million, compared to ISK 1,260 million in the first quarter of 2019.
- Simply Wall St.
How Synthetic Biologics, Inc. (NYSEMKT:SYN) Can Impact Your Portfolio Volatility
If you're interested in Synthetic Biologics, Inc. (NYSEMKT:SYN), then you might want to consider its beta (a measure...
- PR Newswire
Synthetic Biologics Reports 2020 First Quarter Operational Highlights and Financial Results
Synthetic Biologics, Inc. (NYSE American: SYN), a diversified clinical-stage company leveraging the microbiome to develop therapeutics designed to prevent and treat gastrointestinal (GI) diseases in areas of high unmet need, today provided a clinical programs update and reported financial results for the quarter ended March 31, 2020.
- PR Newswire
Synthetic Biologics to Report 2020 First Quarter Operational Highlights and Financial Results on May 5, 2020
Synthetic Biologics, Inc. (NYSE American: SYN), a diversified clinical-stage company leveraging the microbiome to develop therapeutics designed to prevent and treat gastrointestinal (GI) diseases in areas of high unmet need, announced today that the Company intends to release its operational highlights and financial results for the quarter ended March 31, 2020 on Tuesday, May 5, 2020, and to host a conference call the same day at 4:30 p.m. ET. The dial-in information for the call is as follows:
- Yahoo Finance Video
First human trial for coronavirus vaccine begins today: AP
Yahoo Finance’s Anjalee Khelmani joins Zack Guzman and Akiko Fujita on The Ticker to discuss the biotech outlook as coronavirus cases grow in the U.S.
- GlobeNewswire
Results in line with outlook
• Revenue for the fourth quarter of 2019 amounted to ISK 4,935 million, a decrease of 9% from the same period in 2018. • The quarter’s EBITDA amounted to ISK 1,409 million, compared to ISK 1,449 million in the fourth quarter of 2018. The EBITDA margin was 28.6% in the fourth quarter of 2019 compared to 26.7% in the same quarter last year.
- Thomson Reuters StreetEvents
Edited Transcript of SYN earnings conference call or presentation 20-Feb-20 9:30pm GMT
Q4 2019 Synthetic Biologics Inc Earnings Call
- PR Newswire
Synthetic Biologics Reports 2019 Year End Operational Highlights and Financial Results
Synthetic Biologics, Inc. (NYSE American: SYN), a diversified clinical-stage company leveraging the microbiome to develop therapeutics designed to prevent and treat gastrointestinal (GI) diseases in areas of high unmet need, today provided a clinical programs update and reported financial results for the year ended December 31, 2019.
- PR Newswire
Synthetic Biologics Announces Acceptance of Compliance Plan by NYSE American
Synthetic Biologics, Inc. (NYSE American: SYN), a diversified clinical-stage company leveraging the microbiome to develop therapeutics designed to prevent and treat gastrointestinal (GI) diseases in areas of high unmet need, announced today that the NYSE American LLC (the "Exchange") has accepted the Company's plan of compliance (the "Plan") for continued listing on the Exchange.
- Simply Wall St.
We Think Synthetic Biologics (NYSEMKT:SYN) Needs To Drive Business Growth Carefully
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...
- PR Newswire
Synthetic Biologics Receives FDA Guidance at Type C Meeting for SYN-004 (ribaxamase) Phase 1b/2a Clinical Trial in Allogeneic HCT Recipients
Synthetic Biologics, Inc. (NYSE American: SYN), a diversified clinical-stage company leveraging the microbiome to develop therapeutics designed to prevent and treat gastrointestinal (GI) diseases in areas of high unmet need, today announced the receipt of official meeting minutes from the U.S. Food and Drug Administration (FDA) following a Type C meeting held on December 2, 2019 at the Company's request to discuss the development of SYN-004 (ribaxamase) in allogeneic hematopoietic cell transplant (HCT) recipients who are administered intravenous (IV) beta-lactam antibiotics in response to fever.
- GlobeNewswire
Sýn hf.: Financial calendar 2020
Sýn will host its Annual General Meeting and publish its interim condensed and annual consolidated financial statements according to the below financial calendar: Interim.
- GlobeNewswire
Sýn hf.: Landsdowne Partners International Limited - Major shareholder announcements
See attachment: Attachment Landsdowne_SYN_24.12.2019
- Insider Monkey
Is Synthetic Biologics Inc (SYN) Going To Burn These Hedge Funds ?
Hedge funds are known to underperform the bull markets but that's not because they are bad at investing. Truth be told, most hedge fund managers and other smaller players within this industry are very smart and skilled investors. Of course, they may also make wrong bets in some instances, but no one knows what the […]
- PR Newswire
Synthetic Biologics Reports on NYSE American Noncompliance Notice and Compliance Plan
Synthetic Biologics, Inc. (NYSE American: SYN), a diversified clinical-stage company leveraging the microbiome to develop therapeutics designed to prevent and treat gastrointestinal (GI) diseases in areas of high unmet need, today announced it has received written communication from NYSE American LLC (the "Exchange"), the Company's current listing exchange, stating that it is not in compliance with certain continued listing standards as set forth in the NYSE American Company Guide. Based on the Company's quarterly report on Form 10-Q for the quarter ended September 30, 2019, which was filed with the Securities and Exchange Commission (SEC) on November 4, 2019, the Company is below compliance with Part 10, Section 1003 of the NYSE American Company Guide since it reported stockholders' equity of $4.9 million and net losses in five of its most recent fiscal years as of September 30, 2019.
- Thomson Reuters StreetEvents
Edited Transcript of SYN earnings conference call or presentation 4-Nov-19 9:30pm GMT
Q3 2019 Synthetic Biologics Inc Earnings Call
- GlobeNewswire
Sýn hf.: Best operating profit of the year
At the beginning of the year, the accounting treatment of broadcasting license rights was changed, amounts for 2018 have been restated. EBITDA for the first nine months of 2019 was ISK 4,100 million, a decrease of ISK 153 million from same period in 2018. Profit in the first nine months of the year amounted to ISK 384 million which is an increase of ISK 135 million from same period in 2018.
- PR Newswire
Synthetic Biologics Reports Third Quarter 2019 Operational Highlights and Financial Results
-- Enrollment is Ongoing in Phase 2b Investigator-Sponsored Clinical Study of SYN-010, for the Treatment of IBS-C -- -- Conference Call Today, November 4, 2019, at 4:30 p.m. (EST) -- ROCKVILLE, Md. , Nov. ...
- PR Newswire
Synthetic Biologics to Report 2019 Third Quarter Operational Highlights and Financial Results on November 4, 2019
-- Conference Call Scheduled for Monday, November 4, 2019 at 4:30 p.m. ET -- ROCKVILLE, Md. , Oct. 28, 2019 /PRNewswire/ -- Synthetic Biologics, Inc. (NYSE American: SYN), a diversified clinical-stage ...
- PR Newswire
Synthetic Biologics Strengthens U.S. Patent Coverage of SYN-010, Intended for the Novel Treatment of Irritable Bowel Syndrome with Constipation (IBS-C)
ROCKVILLE, Md., Sept. 26, 2019 /PRNewswire/ --Â Synthetic Biologics, Inc. (NYSE American: SYN), a late-stage clinical company developing therapeutics that preserve the microbiome to protect and restore the health of patients, announced today that the U.S. Patent and Trademark Office (USPTO) has granted a U.S. patent and issued a Notice of Allowance for a patent application covering various aspects of the clinical SYN-010 program. Recently granted U.S. Patent No. 10,328,151, which is co-owned by Synthetic Biologics and Cedars-Sinai Medical Center (CSMC) and exclusively licensed to Synthetic Biologics, covers the composition of matter of the SYN-010 clinical agent.
- Simply Wall St.
Does The Synthetic Biologics, Inc. (NYSEMKT:SYN) Share Price Tend To Follow The Market?
If you own shares in Synthetic Biologics, Inc. (NYSEMKT:SYN) then it's worth thinking about how it contributes to the...
- Thomson Reuters StreetEvents
Edited Transcript of SYN earnings conference call or presentation 8-Aug-19 8:30pm GMT
Q2 2019 Synthetic Biologics Inc Earnings Call
